Ozempic & GLP-1 vision loss
Vision loss after Ozempic or another GLP-1 drug?
Start a free case review
- Free
- Confidential
- No fee unless we win
Research links semaglutide to a four- to sevenfold higher risk of NAION, a stroke of the optic nerve that can take sight overnight and rarely gives it back. Parker Waichman LLP, a national firm that has recovered more than $2 billion for its clients, reviews these claims at no cost.
Claims reviewed for people who took
- Ozempic
- Wegovy
- Rybelsus
- Mounjaro
- Zepbound
- Saxenda
Recognition for Parker Waichman LLP
Why now
What the research found, and where the cases stand.
The lawsuits allege that Novo Nordisk and Eli Lilly failed to warn patients and doctors. The companies dispute the claims, and no court has decided them.
- 4×
The risk reported for diabetes patients
Researchers at Harvard’s Mass Eye and Ear reported that people prescribed semaglutide for diabetes were about four times more likely to develop NAION.
- 7×
The risk reported for weight-loss patients
For people prescribed semaglutide for weight loss, the same research reported roughly seven times the risk. A 2025 study in JAMA Ophthalmology described optic-nerve disorders in patients on these drugs.
- MDL 3163
Federal cases are consolidated
In December 2025, federal vision-loss lawsuits were consolidated in the Eastern District of Pennsylvania before Judge Karen S. Marston. The cases are in early discovery, and no global settlement has been reached.
What counts
A claim starts with what the eye doctor found.
Many people never connect a sudden change in vision with a prescription. These are the situations the legal team reviews.
The claim at the center of the litigation
NAION after a GLP-1 drug.
Non-arteritic anterior ischemic optic neuropathy is a stroke of the optic nerve. It usually arrives without pain or warning, often on waking, and the sight it takes generally does not return. Claims are reviewed for people diagnosed after taking Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound or Saxenda.
Helpful, not required to start: prescription history, the pharmacy that filled it, and ophthalmology or diagnostic records.
Every claim depends on its facts. A description here is not a promise that a particular claim qualifies.
Over $2 billion recovered
Verdicts and settlements for injured clients.
Selected results from Parker Waichman LLP. None involved Ozempic or another GLP-1 drug.
- Settlement · 18-wheeler catastrophic injury
- $11M
- Settlement · auto accident
- $10M
- Verdict · general negligence
- $8M
- Nursing home abuse
- $5M
- Verdict · trip and fall
- $4.5M
- Settlement · auto accident
- $4.35M
Prior results do not guarantee a similar outcome. Every case depends on its own facts.
Our attorneys
Led by attorneys who take on drug makers.
Parker Waichman attorneys have served on plaintiffs’ committees in national litigation over drugs and medical devices.
Jerrold S. Parker
Founding Partner
Founded the firm in 1992 after eight years as a Special Agent in the IRS Criminal Investigation Division. Has served on plaintiffs’ steering committees in national drug litigation, including Actos and Zyprexa.
The Best Lawyers in America 2026 · Mass Tort Litigation / Class Actions – Plaintiffs
Melanie H. Muhlstock
Managing Partner · Mass Torts Department
More than 25 years representing plaintiffs in pharmaceutical, medical device and consumer product litigation, with leadership roles in national multidistrict litigations including Hair Relaxer, Elmiron, Tasigna and Zantac.
The National Trial Lawyers Top 100 · since 2014
Raymond C. Silverman
Partner
With the firm since 2004 and a partner since 2011. Has served as lead trial counsel in a medical device case against a major manufacturer and as a member of the trial team in a major pharmaceutical case.
How it works
A clear process, at no cost.
Answer a few questions
The online review takes a few minutes. It is free, confidential, and comes with no obligation.
Talk with our team
Someone from Parker Waichman follows up to listen, explain the options and answer questions. Records help, but nothing is needed to start.
We pursue the claim
If the claim qualifies, our attorneys gather the prescription and medical records and take it as far as it needs to go.
Client reviews
What clients say about the firm.
“I had a great experience with them , everyone was very helpful and sweet.”
Michelle Murphy
“They treated me with tender love and care”
Terrell Weaver
“Wonderful people. They made the whole process if dealing with a gov’t agency so easy.”
Michael Ross
Questions
Questions people often ask.
What is NAION?
Non-arteritic anterior ischemic optic neuropathy is a stroke of the optic nerve: blood flow to the nerve is cut off, and part of the vision in that eye is lost. It usually comes without pain or warning, often overnight, and the lost sight generally does not return.
Which drugs are being reviewed?
Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), and Saxenda (liraglutide). The companies named in the litigation are Novo Nordisk and Eli Lilly.
Has there been a settlement?
No. Federal vision-loss cases were consolidated in December 2025 as MDL 3163 in the Eastern District of Pennsylvania, and they are in early discovery. No global settlement has been reached, and no one can promise an outcome or an amount.
Is this a class action?
No. In a multidistrict litigation the cases are coordinated before one judge, but each person keeps an individual claim based on their own injury and records.
What can a claim seek?
Depending on the facts: medical and ophthalmic care, vision rehabilitation and assistive technology, lost income and earning capacity, home and vehicle modification, pain and suffering, and loss of independence. Families may have claims for loss of consortium or wrongful death.
Is there a deadline?
Yes. Every state sets its own deadline for filing, and it can start running when the injury was diagnosed. A case review is the reliable way to learn how long a particular claim stays open.
What about stomach paralysis or a bowel obstruction?
Gastroparesis, a bowel obstruction requiring surgery, and other serious GLP-1 injuries are also under review. Those claims are handled separately from the vision-loss cases.
What does it cost?
Nothing up front. Parker Waichman works on contingency: no attorney fee unless the firm recovers compensation. The representation agreement explains the terms and how case expenses are handled.
Where we help
Seven offices. Clients nationwide.
Parker Waichman handles mass tort cases nationwide from its offices in New York, New Jersey and Florida. The review works the same from any state.
No office visit is needed. The review, the records and the paperwork can all be handled online and by phone.
Port Washington, NY
6 Harbor Park Drive, Port Washington, NY 11050New York City
59 Maiden Lane, 6th Floor, New York, NY 10038Brooklyn
300 Cadman Plaza West, One Pierrepont Plaza, 12th Floor, Brooklyn, NY 11201Queens
118-35 Queens Boulevard, Suite 400, Forest Hills, NY 11375Melville, NY
201 Old Country Road, Suite 145, Melville, NY 11747West Orange, NJ
80 Main St #265, West Orange, NJ 07052Bonita Springs, FL
27299 Riverview Center Boulevard, Suite 108, Bonita Springs, FL 34134
The next step is a free, private review.
A few questions, answered online. No fee unless we win.